Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB-119 in Newly Diagnosed Type 2 Diabetes Mellitus
NCT03059719Phase 1Completed
- Sponsor
- PegBio
- Start
- Apr 2015
- Primary completion
- Sep 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of visepegenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by PegBio. Primary endpoint: Incidence of treatment-emergent Adverse Events at 3 months. Started Apr 2015; status: completed.
02
Drugs
visepegenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03059719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059719.